SEC Form 4 · accession 0001182489-17-000451

Nexvet Biopharma plc · NVET

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Director

Period of report

Jul 31, 2017

Accepted (ET)

Aug 2, 2017 · 4:09 pm EDT

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001618561

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Ordinary Shares^F3	Jul 31, 2017	D	13,580	$6.72	D	0	D

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Restricted Share Units^F4,F1,F2	—	Jul 31, 2017	D	1,000	D	—	—	Ordinary Shares	1,000	0	D

F1Each Restricted Share Unit ("RSU") is convertible into one ordinary share of the Issuer upon vesting, subject to payment by the holder to the Issuer of the nominal value per share ($0.125).
F2The 1,000 RSUs held by Patel were scheduled to vest and become convertible in quarterly installments of 500 on September 30, 2017 and December 31, 2017. Such RSUs were canceled in the Acquisition, as described below.
F3Disposed of pursuant to a transaction agreement among the Issuer, Zoetis Inc. ("Zoetis") and Zoetis Belgium S.A., a wholly-owned subsidiary of Zoetis ("Bidco"), pursuant to which Bidco acquired all of the issued and to-be-issued ordinary share capital of the Issuer (the "Acquisition").
F4These RSUs, which were not yet vested, were cancelled in the Acquisition in exchange for a total cash payment equal to $6,595, representing the difference between the conversion payment of $0.125 per RSU and the $6.72 consideration per ordinary share payable in connection with the Acquisition, multiplied by the 1,000 ordinary shares issuable upon the vesting and conversion of such RSUs.

Effective July 31, 2017, Patel resigned as a director of the Issuer upon the consummation of the Acquisition.